摘要
目的探讨奥美沙坦酯对2型糖尿病患者的血压及尿微量白蛋白的影响。方法80例24小时尿微量白蛋白排泄量(UAE)在30～300mg的2型糖尿病患者随机分为两组:奥美沙坦酯组40例,口服奥美沙坦酯20mg/d;依那普利组40例口服马来酸依那普利10～20mg/d,疗程12周。分别测量两组治疗前后血压(BP)、尿微量白蛋白(ALB)、血肌酐(Scr)并计算内生肌酐清除率(Ccr)。结果两组治疗后BP、Scr及ALB均显著下降(P<0.05),Ccr明显上升(P<0.05),组间比较无显著性差异(P>0.05);依那普利组咳嗽发生率25%,其中有6例不能耐受咳嗽而退出试验,奥美沙坦酯组无咳嗽病例发生。结论奥美沙坦酯不仅能有效降低血压,而且能降低尿微量白蛋白,不良反应少,依从性好。
Objective To study the effects of Olmesartan Medoxomil on blood pressure and the urine microalbuminuria in patients with type 2 diabetes. Methods Eighty patients with type 2 diabetes were randomly divided into two groups. Olmesartan group （ n = 40） received Olmesartan Medoxomil 20mg/d for 12 weeks, and Enalapril group （ n = 40） received Enalapril Maleate 10 -20mg/d for 12 weeks, The blood pressure ,serum creatinine, ereatinine clearance rate and the urine microalbuminuria at the beginning and after 12 wks of treatment were monitored. Results After 12 weeks treat- ment, blood pressure, the serum creatinine and the urine mieroalbuminuria significantly decreased between Olmesartan group and Enalapril group （ P 〈 0. 05 ） , The creatinine clearance rate had significant difference in two groups （ P 〈 0. 05 ）. There was no significant difference between olmesartan group and enalapril group （ P 〉 0.05 ）. The occurrence of cough in Enalapril group was 25 % , 3 patients discontinued Enalapril therapy due to serious cough. There was no cough patient in Olmesartan group. Conclusion Olmesartan not only reduced blood pressure but also decreased the levels of urine microalbuminuria, and had no obvious adverse reactions and higher compliance.
出处
《医药论坛杂志》
2010年第2期26-27,共2页
Journal of Medical Forum
